Tiragolumab

替瑞利尤单抗

Report date: 2026/04/06 20:01:48

Base Information

Drug NameTiragolumab
Drug Alias NameRG-6058MTIG-7192ARO-7092284RG6058-11RG6058-10
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionT cell immunoglobulin and ITIM domains inhibitors
TargetsT cell immunoglobulin and ITIM domains
Therapy Area/IndicationsMetastatic breast cancerOral Squamous Cell CarcinomaGastroesophageal Junction Neoplasms +[36] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[44] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center GroningenRoche Pharma AgGeorgetown University +[16] 
Inactive CompaniesRoche Global DevelopmentWashington University School Of MedicineYonsei University
Active IndicationsMetastatic breast cancerOral Squamous Cell CarcinomaGastroesophageal Junction Neoplasms +[28] 
Inactive IndicationsLung NeoplasmsMultiple MyelomaCarcinoma, Transitional Cell +[8] 

Other Information

ATC CodeN/A
Related LinksN/A